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Congenital heart defects (CHDs) are common birth defects and result in significant mor-
bidity and global economic impact. Genetic factors play a role in most CHDs; however, 
identification of these factors has been historically slow due to technological limitations 
and incomplete understanding of the impact of human genomic variation on normal 
and abnormal cardiovascular development. The advent of chromosome microarray 
(CMA) brought tremendous gains in identifying chromosome abnormalities in a variety 
of human disorders and is now considered part of a standard evaluation for individu-
als with multiple congenital anomalies and/or neurodevelopmental disorders. Several 
studies investigating use of CMA found that this technology can identify pathogenic 
copy-number variations (CNVs) in up to 15–20% of patients with CHDs with other con-
genital anomalies. However, there have been fewer studies exploring the use of CMA 
for patients with isolated CHDs. Recent studies have shown that the diagnostic yield of 
CMA in individuals with seemingly isolated CHD is lower than in individuals with CHDs 
and additional anomalies. Nevertheless, positive CMA testing in this group supports 
chromosome variation as one mechanism underlying the development of isolated, 
non-syndromic CHD – either as a causative or risk-influencing genetic factor. CMA has 
also identified novel genomic variation in CHDs, shedding light on candidate genes and 
pathways involved in cardiac development and malformations. Additional studies are 
needed to further address this issue. Early genetic diagnosis can enhance the medical 
management of patients and potentially provide crucial information about recurrence. 
This information is critical for genetic counseling of patients and family members. In this 
review, we review CMA for the non-genetics cardiology provider, offer a summary of CNV 
in isolated CHDs, and advocate for the use of CMA as part of the cardiovascular genet-
ics evaluation of patients with isolated CHDs. We also provide perspective regarding the 
benefits and challenges that lie ahead for this model in the clinical setting.
Keywords: chromosome microarray, congenital heart defects, copy-number variation, genetic counseling, clinical 
genetics
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iNTRODUCTiON
Congenital heart defects (CHDs) are a common group of human 
malformations with significant morbidity and economic impact 
(1–3). The prevalence of CHDs in the general population has 
increased with ongoing advancements in medical and surgical 
care so that survival to adulthood is relatively common (4). In 
fact, the population of adults with CHDs is now larger than the 
number of children with CHDs. Despite the birth incidence of 
CHDs remaining relatively stable over the last half-century, the 
true global prevalence of CHDs is likely underestimated (2, 5). As 
more individuals with CHDs survive and reach reproductive age, 
questions regarding heritability, etiology, and recurrence risks 
will be common.
The majority of all CHDs are isolated or non-syndromic, but 
about 20–30% of infants with CHDs have extracardiac malforma-
tions (6). These cases often constitute well-known chromosomal 
and single-gene syndromes (e.g., trisomy 21, trisomy 18, and 
Noonan syndrome). However, complex rare diseases with CHDs 
and multiple congenital anomalies may remain undiagnosed, 
despite expert evaluation and/or the use of genetic testing. 
The underlying causes for the vast majority of CHDs remain 
unknown, especially in the case of apparently isolated or non-
syndromic CHDs.
Approximately 20–30% of CHDs can be attributed to a 
single identifiable genetic or environmental cause (6–8), while 
the remaining cases are thought to be multifactorial. Examples 
of environmental risk factors include maternal disease (like 
maternal hyperphenylalaninemia, rubella, diabetes) and fetal 
teratogens (like alcohol, retinoic acid, and lithium) (9–11). 
CHDs are genetically heterogeneous, with numerous confirmed 
or proposed genetic risk factors, including single-gene variation, 
aneuploidy, chromosome rearrangements, and chromosome dele-
tions/duplications. There are at least 55 human genes implicated 
in CHDs, but over 500 have been identified in mouse models (12). 
It is likely that the same magnitude will be eventually identified 
in humans. However, it is estimated that about 70–80% of CHDs 
have an unknown or multifactorial basis (13, 14). The complex-
ity of genetic contributions probably reflects the complexity of 
cardiac development, and it is accepted that CHD development 
is influenced by multiple genetic (and environmental) factors. A 
multifactorial etiology emphasizing genetic contributions has 
been proposed for CHDs based on recurrence risk data (~1–4% 
across all lesions) and that the fact that family history is a consist-
ent risk factor for CHDs (15–21). These recurrence risks generally 
increase as the number of affected first-degree relatives increases. 
Heritability estimates have been relatively high for specific classes 
of CHDs, namely, the left ventricular outflow tract obstructions 
(LVOTO) (22–24). The available evidence suggests that most 
CHDs have some genetic basis, but this is complicated further by 
variable expressivity and incomplete penetrance, even in families 
with an identified gene mutation or chromosome abnormality 
predisposing to the development of CHDs. Additionally, variants 
in the same genes can result in a spectrum of cardiac phenotypes.
As more individuals with CHDs survive and reach reproduc-
tive age, questions regarding inheritance and recurrence risk 
become increasingly important for reproductive planning and 
counseling. The recent advent of genomic technologies like 
chromosome microarray (CMA) and next-generation sequenc-
ing are providing additional diagnostic ability and refining 
recurrence information. As knowledge of the genetic bases of 
CHDs increases, genetic evaluation, testing, and counseling will 
continue to be important parts of the management of patients 
with CHDs. Current understanding of the multifactorial basis of 
CHDs is growing but far from complete, and cytogenetic analysis 
remains a valuable tool in the evaluation of patients with CHDs.
CYTOGeNeTiCS AND CHROMOSOMe 
MiCROARRAY FOR THe CARDiOLOGiST: 
A Review
Chromosome analysis has been a standard for investigating 
causes for developmental delay/intellectual disability, autism 
spectrum disorder, and congenital anomalies (25, 26). However, 
standard chromosome analysis (i.e., karyotype) has an estimated 
3% detection rate for pathogenic chromosome abnormalities. 
Conventional chromosome analysis detects well-known chro-
mosome aneuploidies (like trisomies 13, 18, and 21 or Turner 
syndrome) in about 10% of cases of CHDs (27). The innovation 
of CMA technology has increased the detection of chromo-
some abnormalities thought to be causative in individuals with 
developmental delay and congenital anomalies from 3% to about 
15–20% (25). Karyotype has a genomic resolution of ~5–10 
million base-pairs (megabases, or Mb); chromosome anomalies 
smaller than this are not consistently or reliably detected. Current 
CMA platforms generally have a genomic resolution of ≥250 
thousand base-pairs (kilobases, or kb), though some platforms 
may have a resolution down to individual genes (1 kb).
One evident challenge of this increased genomic resolution is 
that smaller chromosome variations that have unknown clinical 
significance can be identified (28). This contrasts conventional 
chromosome testing (karyotype) in which large imbalances that 
are detected are all likely pathogenic, and it is uncommon to 
identify variants of unknown significance. Due to the increased 
diagnostic ability of CMA, Miller et al. (25) suggested that they 
be used as a first-line test over standard karyotype – though there 
are certain scenarios in which karyotype may be an ideal test 
(balanced chromosome rearrangements, family histories with 
multiple miscarriages, and/or reduced fertility).
Chromosome microarray is ideal for detecting chromosomal 
imbalances and copy-number variations (CNVs) in patients with 
birth defects and early developmental impairments (25, 29, 30). 
CNVs are generally defined as chromosomal deletions or duplica-
tions that cannot be detected using traditional chromosome analy-
sis, generally sized 1 kb or greater. These CNVs are also referred to 
as “microdeletions” and “microduplications.” Additionally, other 
chromosomal imbalances can be detected like gross aneuploidy 
and higher-order amplifications like triplications. Interpretation 
of the clinical significance of CNVs is typically based on the 
overall size, gene content, location of breakpoints, and deletion 
vs. duplication of a chromosome region. Because the clinical sig-
nificance of many CNVs may be uncertain, the American College 
of Medical Genetics and Genomics published guidelines to assist 
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in predicting the pathogenicity of CNVs (31). Importantly, when 
a dose-sensitive gene is involved in the CNV region, deletion or 
duplication may have profound effects on the function of the gene 
and its protein products and potentially affect other downstream 
gene functions.
Chromosome microarray is performed by two strategies: 
array-based comparative genomic hybridization (aCGH) plat-
forms or by single-nucleotide polymorphism (SNP) platforms. 
Array-based CGH utilizes short DNA sequence oligonucleotide 
probes, whereas SNP-based arrays use SNPs as probes. SNP 
microarrays also provide genotype information by detecting 
allelic copies of single base-pairs throughout the genome. Loss/
gain of oligonucleotide probes on the aCGH platform and loss/
gain of SNPs on the SNP-based platform, both indicate deletions 
and duplications, respectively. Current CMA platforms may 
merge these two strategies in the form of “oligo-SNP” microarrays. 
It is imperative that ordering providers understand the benefits 
and limitations of CMA platforms and be able to interpret and 
communicate results to patients/families.
COPY-NUMBeR vARiATiON AND CHD:  
A Review OF THe LiTeRATURe
While many CNVs are associated with well-described genetic 
syndromes, the role of CNVs in the development of all CHDs is not 
entirely known at this time. A few examples of well-characterized 
syndromes with CHDs caused by CNVs include Williams syn-
drome (7q11.23 deletion), DiGeorge syndrome (22q11.2 deletion 
syndrome), and Smith–Magenis syndrome (17p11.2 deletion). It 
should be noted that these conditions typically include other con-
genital anomalies, dysmorphic features, and neurodevelopmental 
disorders. Assessment by a clinical geneticist should be standard 
in these and similar cases with CHDs due to the presence of 
congenital anomalies and/or developmental delay.
It is estimated that pathogenic CNVs are present in 15–20% 
of patients with CHDs and extracardiac features (32–35). The 
submicroscopic deletions and duplications associated with these 
syndromes generally are not detected by routine chromosome 
analysis; therefore, emphasizing the importance of CMA as a 
part of the diagnostic workup in patients with CHDs. Although 
CNVs play an important role in the development of genetic 
syndromes with CHDs, most CHDs do not occur in the context 
of a genetic syndrome. While the exact contribution of CNVs to 
isolated CHDs is unclear, studies show that ~4–14% of individu-
als with isolated CHDs have pathogenic or suspected pathogenic 
CNVs (36, 37), though others have suggested 3–10% (13, 38). 
Geng et  al. (39) retrospectively reviewed 514 CHD cases that 
had CMA testing, contrasting the yields between isolated and 
syndromic cases. They found pathogenic or likely pathogenic 
results for 4.3–9.3% of isolated CHD cases. The yield was higher 
for syndromic cases when excluding aneuploidies. Additional 
large-scale studies are necessary to further specify and support 
these estimates.
The few studies that have investigated the contribution of 
CNV to the development of isolated CHDs are providing insight 
into additional genes and pathways involved in cardiovascular 
development and malformation. These studies can also provide 
additional understanding about heritability, recurrence, variable 
expression, and incomplete penetrance of CHDs in families. In 
the studies summarized in Table 1, there are examples of appar-
ently isolated CHDs that were found to have CNVs overlapping 
known syndromic regions [e.g., 22q11.2 deletion and duplication, 
16p11.2 duplication; see Silversides et  al. (40)]. It is unclear if 
those patients had been evaluated for and/or diagnosed clinically 
with a genetic syndrome, or they had been unrecognized or 
only presented with mild features. These studies have not only 
provided additional information about candidate genes and path-
ways associated with CHDs or risk of CHDs but also highlight 
that even apparently isolated CHDs may actually be syndromic. 
This information can inform patient evaluation and may lead to 
early diagnosis, which can have positive impact on management 
and genetic counseling. Utility of genetic testing depends largely 
on accurate phenotyping of the CHD lesion and the presence of 
extra-cardiac features. Further studies with meticulous pheno-
typing and goals to assess broad classes of CHDs lesions should 
be undertaken to further refine this estimate. This also highlights 
the critical importance of involvement of clinical geneticists in 
the evaluation of seemingly isolated CHDs.
CMA FOR THe CHD POPULATiON: 
iNTeRPReTATiON OF ReSULTS
Chromosome microarray is recommended as a first-tier clinical 
genetic test in cases of isolated CHDs due to the relatively high 
rate of detection of pathogenic CNVs. Positive results in the 
patient with isolated CHDs can provide important information 
for practitioners and family members when making decisions 
regarding ongoing care and family planning. The negative CMA 
result can also be critical in guiding next steps for care and in lim-
iting the differential for any given patient. Many well-described 
chromosomal conditions can be eliminated as diagnoses by a 
normal CMA result. This elimination can guide further genetic 
testing decisions and options for additional clinical testing to 
hone in on the exact diagnosis for the patient.
While implementing the use of CMA in the diagnostic evalu-
ation of patients with CHDs has uncovered previously unknown 
pathogenic chromosome variation, it has also presented the 
unique challenges of interpreting variants of uncertain signifi-
cance (VUS). Designation of VUS is typically reserved for dele-
tions or duplications that have not been previously described, 
have not been seen in studied control populations, and for which 
there are incomplete data regarding genes in the affected region 
(45). Adding to this difficulty are the concepts of incomplete 
penetrance and variable expressivity. Some VUS results have 
been reported in the literature with highly variable phenotypic 
features due to variable expressivity, adding further complexity 
to the interpretation of the contribution of any given VUS to the 
phenotype of the patient. Incomplete penetrance of CNVs also 
complicates the recommendations and counseling provided to 
families, as accurate risk prediction for certain health concerns 
cannot be provided. Of particular concern is the patient with sig-
nificant morbidity who inherits a CNV of unknown significance 
TABLe 1 | A summary of CNvs identified by CMA in non-syndromic CHDs reported in the literature.
Study CNvs (limited list) Confirmed or putative candidate 
genes for CHDs noted by authors 
(limited list)
CHD types in study Other notes
Thienpont 
et al. (41)
4q34 deletion AS, TOF, CoA, VSD, 
truncus arteriosus, PS5q35.1 deletion NKX2-5
9q34.3 deletion NOTCH1
22q11.2 duplication
Erdogan 
et al. (36)
1q21.1 deletion GJA5 Any CHD: majority were 
VSD; TOF, PS, CoA, ASD, 
AS, HLHS, and AVSD
The 17p11.2 deletion is causative for Smith–
Magenis syndrome. Features of this disorder 
were not appreciated until after the test result
2p22.3 duplication LTBP1
17p11.2 deletion (See note in last column)
22q11.2 duplication TBX1, CRKL
Greenway 
et al. (42)
1q21.2 deletion and duplication GJA5, PRKAB2, CHD1L, BCL9 TOF Study involved only subjects with TOF
2p23.3 duplication ASXL2, KIF3C, RAB10
3p25.1 duplication RAF1
9q34.3 deletion NOTCH1
20p12.2 deletiona JAG1
22q11.2 deletiona TBX1, CRKL
Silversides 
et al. (40)
1q21.1 duplication GJA5 TOF Study involved only subjects with TOF
1q32.2 deletion PLXNA2
3p25.1 deletion RAF1
7q21.11 deletion SEMA3E, SEMA3D
7p15.3 deletion DNAH11
7p22.2 deletion SNX8
8p23.1 deletiona GATA4, ANGPT2
8p23.3 duplication ARHGEF10
Soemedi 
et al. (37)
1q21.1 duplication GJA5 TOF, ASD, VSD, CoA, 
complex left-sided defect, 
TAPVR
Other rare CNVs identified with unconfirmed 
candidate genes associated with cardiac 
development; TOF overly represented
4q34 deletion HAND2
5q14.1q14.3 duplication SSBP2, TMEM167A, VCAN, EDIL3
5q35.3 duplication CNOT6
8p23.1 GATA4
Fakhro et al. 
(43)
1q32.3 duplication NEK2 Heterotaxy with: D-TGA; 
dextrocardia; VSD, ASD, 
PAPVR; malposed great 
arteries, CoA
Study involved CHDs with heterotaxy
2p25.1 duplication ROCK2
3p24.1-p23 deletion TGFBR2, RBMS3, GADL1
3p24.1 duplication TGFBR2, GADL1
7q36.1 deletion GALNT11
8p23.1 deletion GATA4
9q34.11 duplication NUP188
Zhao et al. 
(44)
3q21.3 duplication PLXNA1 ASD, VSD, PDA, TOF, 
Ebstein anomaly, tricuspid 
incompetence
Study involved 100 Han Chinese subjects
16q23.1 duplication WWOX
18q23 duplication NFATC1
22q11.2 deletiona TBX1, CRKL
AS, aortic stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; CHD, congenital heart defect; CoA, coarctation of the aorta; D-TGA, dextro-transposition of the 
great arteries; HLHS, hypoplastic left heart syndrome; PAPVR, partial anomalous pulmonary venous return; PDA, patent ductus arteriosus; PS, pulmonary stenosis; TAPVR, total 
anomalous pulmonary venous return; TOF, tetralogy of Fallot; VSD, ventricular septal defect.
aIt was unclear if these reports included patients with clinical diagnoses of syndromic disorders (i.e., DiGeorge syndrome for 22q11/2 deletion or Alagille syndrome for the 20p12.2 
deletion). It could be that these reports were either unrecognized syndromes or individuals who were mildly affected.
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from a typical-appearing parent. This situation requires discern-
ment from both the calling laboratory and the health care team in 
order to provide an accurate risk assessment to the “unaffected” 
parent as well as the affected child and the significance of the 
familial CNV. It may also be difficult to provide accurate recur-
rence risk information for reproductive decision-making if the 
contribution of the CNV to the affected patient’s phenotype 
is unclear. Parental studies should be offered in the event that 
a VUS is found in a child in order to aid in interpretation and 
significance of the CNV regardless of whether the parents have 
similar or dissimilar phenotypes. However, insurance coverage 
and justification of how this information will impact the parental 
medical management may prove to be difficult and require the 
adamant support from the health care team in order to secure 
insurance coverage. The likelihood of discovering a VUS should 
be outlined to the family as part of the pretest informed consent 
process.
Another challenge when using CMA in the CHD population 
is the “one-hit fallacy” or the notion that any specific CHD is 
caused by one particular genetic variation alone. CHD is a 
multifactorial disease caused by both environmental and genetic 
factors. The contribution of any one CNV to the overall risk for 
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CHDs is difficult to assess. While ~20% of CHDs can be attrib-
uted to a known cause (syndromic, teratogenic, etc.), the vast 
majority of CHDs is non-syndromic, isolated defects exhibiting 
a multifactorial inheritance pattern. In any one case of isolated 
CHD, there may be multiple genes involved, each providing a 
minimal contribution to the patient’s risk, interacting with 
various environmental factors to form a complex model of CHD 
development.
One area in which health care providers can aid in the interpre-
tation of a CNV is to provide accurate and thorough phenotyping 
prior to the completion of genetic testing. By performing CMA 
for a patient, a genome-wide net is cast in the hopes of finding 
an explanation for the patient’s particular phenotype. By casting 
such a wide net, results can often be complicated by overlapping 
clinical diagnoses and lack of genotype/phenotype correlations. 
CNVs must also be considered in the context of size, location, and 
gene involvement. Understanding of the clinical significance of a 
CNV involving genes that have yet to be well described or that 
have yet to be implicated in a particular phenotype can prove to 
be difficult. One example of distinguishing cardiac phenotypes 
is the presence of an atrial septal defect (ASD) and the classifica-
tion of primum vs. secundum ASD. Primum ASDs are within the 
spectrum of atrioventricular canal defects, whereas secundum 
ASDs are a malformation of the atrial septum (46). This classifica-
tion distinguishes the CHDs from a developmental perspective 
and can aid in the interpretation by narrowing focus on genes 
associated with the responsible developmental process. Accurate 
and specific phenotyping will require coordinated efforts from 
cardiologists and clinical geneticists.
The process of interpretation of CNVs is ongoing and con-
stantly evolving. As CMA continues to be performed as a first-line 
test for patients with CHDs, CNVs classified as VUS will continue 
to present challenging clinical scenarios for health care providers. 
While it is important that both the laboratory and the health care 
team work together to interpret CNVs and assign appropriate 
labels of pathogenicity, it is also important to acknowledge current 
limitations in our understanding of the human genome and the 
contribution of variation to cardiovascular disease phenotypes. 
As our knowledge continues to increase, the opportunity to 
further refine and identify novel phenotypes presents an exciting 
challenge for the cardiovascular genetics community.
THe iMPORTANCe OF GeNeTiCS CARe 
PROviDeR iNvOLveMeNT wiTH CHD
Our understanding of the association between CNVs and syn-
dromic genetic diagnoses is increasing. There are many examples 
of newly described microdeletion and microduplication condi-
tions with CHDs (47). Variable expressivity of these conditions 
and the generally small number of patients described in the 
literature can make it difficult to recognize associated features 
and make an accurate diagnosis. Even more well-described syn-
dromes, such as DiGeorge syndrome, 1p36 deletion syndrome, 
and Williams syndrome, can go undetected for many years in 
patients with mild or variable presentations. Early involvement 
of the clinical genetics team provides the opportunity for earlier 
recognition of syndromic conditions, which can result in more 
comprehensive medical interventions and therapies as well as 
improved prognosis, compared to those patients who receive a 
syndromic diagnosis later in life. There is also increasing recogni-
tion that many delineated syndromes have broader phenotypic 
variability than previously thought (34, 35, 48). Many syndromes 
may not be recognized earlier in life due to absence of the 
“classic” defining features (49). CHD, which is present at birth, 
can provide a framework for the genetics provider to begin the 
process of creating a differential for the patient due to the higher 
prevalence of certain types of CHD lesions in certain genetic 
conditions (50, 51). CMA, as a first-line genetic test, can detect 
causative CNVs for many syndromic conditions with a CHD 
component well before other hallmark features of the diagnosis 
can be recognized. When CMA is negative, additional genetic 
testing, including sequencing of genes associated with known 
conditions and/or whole-exome sequencing, may be warranted 
for patients with multi-system involvement or features suggestive 
of a particular genetic condition.
Clinical geneticists and genetic counselors serve as valuable 
resources to family members of patients with CHD. Early syndro-
mic recognition by the geneticist physician and continued follow-
up by a genetic counselor can provide valuable information to 
the family regarding the anticipation of developmental delays 
and disabilities, available therapies, and social services that might 
benefit their child. Early diagnosis can also refine recurrence risk 
estimates and allow families to make informed reproductive 
planning decisions. Genetic evaluation and risk assessment can 
prove to be a powerful tool for empowering families to use genetic 
information to make informed health decisions. A unique role of 
the genetics team is the ability to clearly communicate familial 
risk for CHDs and recommendation of family screening proto-
cols. First-degree family members with certain types of CHDs are 
at an increased risk to also have undetected CHDs. For example, 
LVOTO heart defects are understood to be a heritable class of 
defects, and family members have an increased risk of also having 
a CHD (22). Studies show that in up to 20% of cases, there is at 
least one other affected relative in the family with variability in 
type of LVOTO present. Therefore, screening by echocardiogram 
is recommended for all first-degree family members of someone 
affected with an LVOTO class of heart defect (23, 52).
An emphasis must be placed on the coordinated efforts of the 
cardiologist, clinical geneticist, and genetic counselor in the evalu-
ation, management, and follow-up with patients with CHDs and 
their family members. This same approach should be used when 
considering CMA testing and interpretation in this population. A 
multidisciplinary approach provides a comprehensive care model 
for patients and families. Genetic testing through the use of CMA, 
even in patients with apparently isolated CHDs, can aid in deline-
ation of diagnosis, accurate risk assessment for family members, 
and refinement of recurrence risk estimates for reproductive 
decision-making. Accurate phenotyping and diagnosis can 
improve patient outcomes and access to necessary evaluations, 
therapies, and social services. Genetic counseling and education 
can empower patients with CHDs and their relatives to use their 
understanding of the genetic basis of cardiovascular disease to 
in turn choose effective strategies for health maintenance and 
appropriate psychosocial coping mechanisms.
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